Published in AIDS Weekly, May 1st, 2006
Study 1: An HIV integrase-E2C zinc finger fusion protein strategy achieves site-specific integration.
"In vitro studies using fusion proteins consisting of human immunodeficiency virus type 1 integrase (IN) and a synthetic polydactyl zinc finger protein EX, a sequence-specific DNA-binding protein, showed that integration of retroviral DNA can be biased towards a contiguous 18-bp EX-recognition site," scientists writing in the Journal of Virology report.
"To determine whether the fusion protein strategy can achieve site-specific...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-05-01)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.